SHIVOM
THE IDEA
The world of healthcare is changing. Two revolutionary technologies, genomics, and blockchain, are poised to significantly improve health and well-being across the globe. Genomic medicine can enhance the understanding and treatment of as many as 7,000 rare diseases, alongside cancers, complex and long-term disease such as cardiovascular and neurodegenerative conditions, and infections.
WHY NOW?
The cost of DNA sequencing has fallen significantly. It is anticipated that by the end of the decade it will be possible to generate a person’s entire genome for less than $100. Looking ahead further, we will see dramatically lower costs for genomic analysis services.
Cost per Genome
GENOME SEQUENCING COMPANIES WILL BE COMPETING SOON. THE TIME IS NOW TO JOIN SHIVOM.
Genomic sequencing provides many benefits:
- Identifying the best course of care for patients with a particular condition
- Prevention of disease in healthy individuals
- Prediction of disease risk
- Disease diagnosis
- Treatment, including choice of most effective medication and dosage
- Disease prognosis
- Identifying new drug targets
PEOPLE WHO GET GENOMIC SEQUENCING WILL BE IN A
BETTER POSITION TO MANAGE THEIR HEALTH.
Stakeholder Structure:
Using permission-based smart-contracts, access to genomic information will be
authorized by the blockchain while potential incentivization to the user or donor
remains secure and anonymized.
Blockchain technology helps users transmit genomic data or quantifiable lifestyle information to other stakeholders. At the same time, the patient can keep sensitive information, such as substance abuse data, hidden from certain stakeholders.
DRUG DEVELOPMENT
Pharmaceutical, biotech, insurance and data donors all within the same hub
Genomics and artificial intelligence present a unique opportunity to revolutionize R&D programs, especially screening for drug targets and corresponding drug candidates. The significant cost associated with drug development is linked to the ability to access high-quality and validated datasets from patients.
We are currently engaging with partners in leading pharmaceutical/biotech companies and clinical research organizations (CROs) to allow access to our services, as well as offer the opportunity to sponsor genomic testing on a mass level.
GLOBAL GENETIC COUNSELOR NETWORK
A global network of genomic/health counselors and laboratories.
We aim to build a global network of genetic counselors who can also form a telemedicine ecosystem (in case people in rural areas have no direct access to healthcare). Eventually, most people will undergo genetic testing and counseling, not only those with clearly elevated genetic risks.
Our counselors and laboratories will also work as an information hub. As genomic data become more common in the clinic, it is imperative that clinical scientists and physicians use automated and standardized tools which employ up-to-date methods and curated publications.
The growth rate of genomic data acquisition over the last decade has been truly astonishing, with the total amount of sequence data produced doubling approximately every seven months.
Global Genomics Personalized Health Market Revenue by Region in 2017
TOPLINE NUMBERS
Global healthcare market USD$ 8.7 trillion by 2020
CAGR 14.9% (2017-2025)
Precision medicine market USD$ 40 billion by end of 2016 CAGR 10-11% by 2025 — expected to reach up to 112.6 billion.
This includes big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and more.
TOKENS
The OmiX Token:
The OmiX token is a key component that enables buying, trading, incentivizing and other services. The token is the fuel of the Shivom ecosystem, as well as part of the governance of the system.
Benefits of OmiX tokens:
- Ability to acquire premium services in the Shivom ecosystem
- Ability to acquire genome sequencing kits
- Ability to sponsor sequencing projects
- Ability to acquire access to health/fitness apps from 3rd party providers
- Ability to access the genome database
- Ability to pay donors for data/participation in research studies
- Ability for service providers to use the platform
TOKEN SALE: USE OF PROCEEDS
The level of funding received dictates the distribution of funds.
However, reserve structure allows us to reduce the volatility along
the way while achieving long-term objectives.
20% Platform Development
Database building, UI, APIs, and metadata curating. A large part of this budget will
be used to make the platform secure and scalable. From there we will implement
new features and create the open marketplace.
11% Operations & Business Development
Day-to-day operations, team building (developers, geneticists, marketers and
product managers). Forming the Foundation.
10% Non-Profit R&D Platform
Drug discovery platform combining elements of Big Data analytics, artificial
intelligence, genomics, proteomics, lipidomics, and metabolomics.
21% Marketing & Forming Partnerships
Ongoing community-building events public communications via traditional
marketing channels and persona-based approaches. This also includes educational
materials, roadshows, collaboration with other genomics-initiatives, organizing
events and conferences, and KOL management.
5% Legal
Regulatory compliance for all markets Shivom operates in.
2% Initial PoC
First sequencing project in hospitals in rural India.
6% Data Storage
Forecasted to sustain the platform during the first few years.
25% Laboratories
Setting up a global network of laboratories and counseling services.
THE TEAM
Dr. Axel Schumacher Co-Founder & CEO
Ph.D. in Genetics, over 20 years of R&D leadership experience in genomics, epigenetics, biomarker discovery, Bio-IT, aging & longevity. Author of the ‘Blockchain & Healthcare Strategy Guide’, the standard compendium for the healthcare industry. Faculty Member, Blockchain Research Institute, Toronto.
Gourish Singla Co-Founder & COO
Serial Entrepreneur. Background in investment banking and wealth management. COO for the #4 company in the digital health space. Singlehandedly established a unit and drove it $35 million revenue
Sally Eaves Co-Founder & CMO
Experienced Chief Technology Officer, Top 10 blockchain influencer, practicing Professor of FinTech, Global Strategic Advisor, and member of the Forbes Technology Council.
Global executive with extensive venture capital, cross-border advisory, corporate finance and entrepreneur experiences. As an investor, he focuses on FinTech / blockchain, frontier technologies and ventures based on his collective VC experiences to date. An advisor to multiple blockchain / ICOs and tech startups in Silicon Valley and beyond; and continues to maintain a pulse on latest technological innovations. Advisor and mentor to accelerators, incubators, entreprenuerial hubs & governments worldwide.
Akash Gaurav Co-Founder & CTO
Blockchain expert, started India’s first blockchain company, Auxesis Group (Top 100 blockchain companies), Blockchain Lab, India, and is an advisor to the blockchain startup Cashaa ($15 million raised).
CONTACT US
WIBESITE | WHITEPAPER | TELEGRAM | TWITTER |
FACEBOOK | INSTAGRAM | EMAIL |
AUTHOR
MY BITCOINTALK |
Tidak ada komentar:
Posting Komentar